Itrawall-DS Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the fungal cytochrome P450 enzyme 14α-demethylase, which is essential for converting lanosterol to ergosterol, a critical component of the fungal cell membrane. Disruption of ergosterol synthesis results in increased membrane permeability and ultimately fungal cell death. Itrawall-DS is effective against a wide range of fungal pathogens, including dermatophytes, yeasts such as Candida species, and molds like Aspergillus species. It is commonly prescribed for conditions such as onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and other systemic mycoses. The capsule formulation allows for oral administration, with absorption enhanced when taken with food. Itrawall-DS should be used under medical supervision, with dosage and duration tailored to the specific infection and patient response. Caution is advised in patients with hepatic impairment, and potential drug interactions should be reviewed due to itraconazole’s effect on cytochrome P450 enzymes. Adverse effects may include gastrointestinal disturbances, headache, and elevated liver enzymes. Monitoring liver function during prolonged therapy is recommended to ensure safety and efficacy.